Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus

被引:218
作者
Lavillette, D
Tarr, AW
Voisset, C
Donot, P
Bartosch, B
Bain, C
Patel, AH
Dubuisson, J
Ball, JK
Cosset, FL
机构
[1] Ecole Normale Super Lyon, LVRTG, INSERM, U412,IFR128,BioSci Lyon Gerland, F-69364 Lyon 07, France
[2] Univ Nottingham, Queens Med Ctr, Inst Infect Immun & Inflammat, Nottingham NG7 2RD, England
[3] Univ Nottingham, Queens Med Ctr, Div Microbiol, Nottingham NG7 2RD, England
[4] Inst Pasteur, Inst Biol Lille, CNRS, UPR2511, F-59019 Lille, France
[5] BioSci Lyon Gerland, IFR128, FRE 2736, CNRS BioMetrieux, Lyon, France
[6] Univ Glasgow, Inst Virol, MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland
基金
中国国家自然科学基金;
关键词
D O I
10.1002/hep.20542
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Because of the lack of a robust cell culture system, relatively little is known about the molecular details of the cell entry mechanism for hepatitis C virus (HCV). Recently, we described infectious HCV pseudo-particles (HCVpp) that were generated by incorporating unmodified HCV E1E2 glycoproteins into the membrane of retroviral core particles. These initial studies, performed with E1E2 glycoproteins of genotype 1, noted that HCVpp closely mimic the cell entry and neutralization properties of parental HCV. Because sequence variations in El and E2 may account for differences in tropism, replication properties, neutralization, and response to treatment in patients infected with different genotypes, we investigated the functional properties of HCV envelope glycoproteins from different genotypes/subtypes. Our studies indicate that hepatocytes were preferential targets of infection in vitro, although HCV replication in extrahepatic sites has been reported in vivo. Receptor competition assays using antibodies against the CD81 ectodomain as well as ectopic expression of CD81 in CD81-deficient HepG2 cells indicated that CD81 is used by all the different genotypes/subtypes analyzed to enter the cells. However, by silencing RNA (siRNA) interference assays, our results show that the level of Scavenger Receptor Class-B Type-I (SR-BI) needed for efficient infection varies between genotypes and subtypes. Finally, sera from chronic HCV carriers were found to exhibit broadly reactive activities that inhibited HCVpp cell entry, but failed to neutralize all the different genotypes. In conclusion, we characterize common steps in the cell entry pathways of the major HCV genotypes that should provide dues for the development of cell entry inhibitors and vaccines.
引用
收藏
页码:265 / 274
页数:10
相关论文
共 50 条
[1]   THE NATURAL-HISTORY OF COMMUNITY-ACQUIRED HEPATITIS-C IN THE UNITED-STATES [J].
ALTER, MJ ;
MARGOLIS, HS ;
KRAWCZYNSKI, K ;
JUDSON, FN ;
MARES, A ;
ALEXANDER, WJ ;
HU, PY ;
MILLER, JK ;
GERBER, MA ;
SAMPLINER, RE ;
MEEKS, EL ;
BEACH, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (27) :1899-1905
[2]   Correlation between virus genotype and chronicity rate in acute hepatitis C [J].
Amoroso, P ;
Rapicetta, M ;
Tosti, ME ;
Mele, A ;
Spada, E ;
Buonocore, S ;
Lettieri, G ;
Pierri, P ;
Chionne, P ;
Ciccaglione, AR ;
Sagliocca, L .
JOURNAL OF HEPATOLOGY, 1998, 28 (06) :939-944
[3]   Novel cell culture systems for the hepatitis C virus [J].
Bartenschlager, R ;
Lohmann, V .
ANTIVIRAL RESEARCH, 2001, 52 (01) :1-17
[4]   Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor [J].
Bartosch, B ;
Vitelli, A ;
Granier, C ;
Goujon, C ;
Dubuisson, J ;
Pascale, S ;
Scarselli, E ;
Cortese, R ;
Nicosia, A ;
Cosset, FL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (43) :41624-41630
[5]   In vitro assay for neutralizing antibody to hepatitis C virus:: Evidence for broadly conserved neutralization epitopes [J].
Bartosch, B ;
Bukh, J ;
Meunier, JC ;
Granier, C ;
Engle, RE ;
Blackwelder, WC ;
Emerson, SU ;
Cosset, FL ;
Purcell, RH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (24) :14199-14204
[6]   Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes [J].
Bartosch, B ;
Dubuisson, J ;
Cosset, FL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (05) :633-642
[7]   GENETIC-HETEROGENEITY OF HEPATITIS-C VIRUS - QUASI-SPECIES AND GENOTYPES [J].
BUKH, J ;
MILLER, RH ;
PURCELL, RH .
SEMINARS IN LIVER DISEASE, 1995, 15 (01) :41-63
[8]  
CALVO D, 1993, J BIOL CHEM, V268, P18929
[9]   Oral health in patients with hepatitis's C virus infection: an underestimated problem? [J].
Carozzo, M .
ORAL DISEASES, 2001, 7 (05) :267-270
[10]   VACCINATION OF CHIMPANZEES AGAINST INFECTION BY THE HEPATITIS-C VIRUS [J].
CHOO, QL ;
KUO, G ;
RALSTON, R ;
WEINER, A ;
CHIEN, D ;
VANNEST, G ;
HAN, J ;
BERGER, K ;
THUDIUM, K ;
KUO, C ;
KANSOPON, J ;
MCFARLAND, J ;
TABRIZI, A ;
CHING, K ;
MOSS, B ;
CUMMINS, LB ;
HOUGHTON, M ;
MUCHMORE, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) :1294-1298